Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Johnson and Johnson
Medtronic
Boehringer Ingelheim
Merck

Last Updated: October 1, 2022

Investigational Drug Information for Exatecan


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Exatecan?

Exatecan is an investigational drug.

There have been 18 clinical trials for Exatecan. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2001.

The most common disease conditions in clinical trials are Sarcoma, Liver Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Daiichi Sankyo Inc., Daiichi Sankyo, Inc., and Bio-Thera Solutions.

Recent Clinical Trials for Exatecan
TitleSponsorPhase
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for InjectionBio-Thera SolutionsPhase 1
Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009Bio-Thera SolutionsPhase 1
Exatecan Mesylate in Treating Children With Relapsed or Refractory RhabdomyosarcomaDaiichi Sankyo Inc.Phase 2

See all Exatecan clinical trials

Clinical Trial Summary for Exatecan

Top disease conditions for Exatecan
Top clinical trial sponsors for Exatecan

See all Exatecan clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Johnson and Johnson
Medtronic
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.